BioAge Labs, based in California, announced it has expanded its AI-driven drug discovery platform by incorporating data from a leading European biobank. According to the company, the integration will allow researchers to analyze longitudinal health data and biological samples from over half a million individuals, aiming to identify new drug targets that promote healthy aging.
The company said that access to this extensive dataset will enhance its ability to discover and validate compounds targeting human aging and age-related diseases. BioAge Labs claims its platform leverages multi-omic data—covering genomics, proteomics, and metabolomics—to predict the biological mechanisms behind aging and disease progression.
By combining biobank data with its proprietary machine learning tools, the company aims to accelerate the development of therapies intended to extend healthy lifespan. BioAge Labs said this move supports its broader strategy to translate insights from human data directly into clinical-stage drug programs.
The company added that it expects the integration to advance ongoing research into age-related conditions, including cardiovascular disease and neurodegeneration, though specific timelines were not disclosed.
BioAge Labs’ expanded platform now includes data drawn from both U.S. and European populations, which the company claims will strengthen its efforts to address diverse health needs across global markets.
